Alto Neuroscience, Inc. (NYSE:ANRO) Position Boosted by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its holdings in Alto Neuroscience, Inc. (NYSE:ANRO) by 619.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,315 shares of the company’s stock after purchasing an additional 3,715 shares during the quarter. BNP Paribas Financial Markets’ holdings in Alto Neuroscience were worth $49,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. FMR LLC lifted its holdings in shares of Alto Neuroscience by 1.4% during the third quarter. FMR LLC now owns 2,363,056 shares of the company’s stock valued at $27,033,000 after purchasing an additional 32,040 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Alto Neuroscience by 80.3% in the third quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after buying an additional 370,612 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Alto Neuroscience by 182.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock worth $2,139,000 after acquiring an additional 120,779 shares in the last quarter. TD Asset Management Inc purchased a new position in shares of Alto Neuroscience in the second quarter worth approximately $928,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Alto Neuroscience by 84.5% during the third quarter. The Manufacturers Life Insurance Company now owns 65,805 shares of the company’s stock valued at $753,000 after acquiring an additional 30,135 shares during the period.

Analysts Set New Price Targets

ANRO has been the subject of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Wedbush downgraded Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $29.00 to $4.00 in a report on Wednesday, October 23rd. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Finally, Robert W. Baird dropped their target price on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO opened at $3.72 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. Alto Neuroscience, Inc. has a one year low of $3.56 and a one year high of $24.00. The business’s 50-day moving average price is $5.75 and its two-hundred day moving average price is $9.77.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.05. Sell-side analysts anticipate that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.